Elevated baseline NT-proBNP and hsTn appear to be related to worse outcomes in patients undergoing androgen deprivation for prostate cancer, particularly when GnRH agonists are used; however higher quality evidence is needed. The gene discussed is NPPB; the disease is prostate cancer.